In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is linked with improved clinical outcomes compared with conventional therapies.

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

“This is the first major study to compare the effect of two common diabetes treatments — GLP-1 medicines and metformin — on dementia risk, using health records from more than 174,000 people. The ...

For older patients with cancer and T2D, GLP-1 RA use is associated with lower all-cause mortality than DPP4i use.